Q321 results were a letdown compared to the previous quarter as COVID-19 continues to burst HA players’ bubble but hopes for a return to normal prevail.

Spring 2021 brought on much relief to the US Joint Fluid Replacement market and the summer looked promising for a return to normal business conditions. However, as more cases of COVID-19 Delta variant were reported, especially in key hyaluronic acid (HA) states, like Texas and Florida, companies were left as though their bubble got burst. Some players expressed concerns that volumes could be depressed for Q421 since it does not seem to be picking up as fast as they projected. But, for Q321 and for the most part, the majority of HA market players did report positive revenue increases in the third quarter.

Among the many topics covered in detail in our comprehensive Q321 US Joint Fluid Replacement Market Recap* are:

Procedures using surgical matrices maintained their new normal, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices maintained their new normal, though the resurgence of Delta variant across the northern tier of states may put a dent in the market following deferrals of procedures in various regions as the COVID-19 Delta variant caused more procedural headwinds.

Among the many topics covered in detail in our comprehensive Q321 US Surgical Matrices Market Recap* are:

We are pleased to announce that Jim Petricek has joined the team at SmartTRAK as General Manager, Orthobiologics and Regenerative Medicine. Jim has 20+ years operational and management consulting experience in orthobiologics and regenerative medicine with roles in product development, marketing and business development, including prior management positions with BioMimetic Therapeutics and Synthes.

Meet Jim Petricek:

What is your role with SmartTRAK? General Manager Orthobiologics and Regenerative Medicine; Lead Analyst Orthobiologics

What do you like about SmartTRAK? I’ve had the pleasure of interacting with SmartTRAK for many years. The group is very knowledgeable in their respective fields, and while I’m sure not every day is bliss, there is a very palpable sense that everyone really enjoys being part of the SmartTRAK team.

Cheryl Blanchard, President and CEO of Anika Therapeutics, discusses the Company’s metamorphosis from a partnered, single product company into a customer-facing, global joint preservation market player, in an interview with SmartTRAK.

Cheryl Blanchard, PhD, discusses the Company’s remarkable achievements amid a global healthcare crisis and progress made as Anika continues to execute on its Transformational Growth Strategy and grand plan in an interview with SmartTRAK at the American Academy of Orthopaedic Surgery (AAOS) 2021 in San Diego, California. To find out more, click on the following audio recording. A link to download the complete transcript of the interview is also provided below.

This Year’s AAOS Annual Meeting was no different--scientific bodies are still divided on the efficacy of HA therapy and it remains a “bête noire” sitting outside of the gold standard for the treatment of patients affected by knee OA.

For some time now, hyaluronic acid (HA) viscosupplement injections (aka intra-articular (IA) HA injections) have become a standard and an integral part of the physician’s armamentarium in the treatment continuum for an ever-growing number of patients suffering from knee osteoarthritis (OA). With OA universally established as the most prevalent form of arthritis afflicting the US population, SmartTRAK estimates that approximately 2.3 million HA injection procedures will be performed for knee OA alone.  Yet, confusion and debates persist over the efficacy of HA therapy, product composition and source of the HA, volume and number of injections, treatment cost and, more recently, regulatory classification for HA products. SmartTRAK believes that the plethora of studies on the use of HA injection that show varied results is ...

To download and read the complete article by Freddy Buntoum, Sr. Analyst, Orthobiologics and Regenerative Medicine at SmartTRAK, please click the button below.

Procedures using surgical matrices rebounded to normal levels again, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices returned to approximately normal levels, though the Delta variant may make that recovery short-lived, as recently observed in Texas. The US Surgical Matrices market rebounded strongly in Q221 according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* continued to lead the US Surgical Matrices market, with Becton Dickinson* (BD) bouncing back nearly as strongly.

Among the many topics covered in detail in our comprehensive Q221 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants came roaring back from its pandemic depths in Q221 as procedures returned to normal.  

As surgical procedures returned to approximately normal levels, the US Hemostats and Sealants market grew +51.1% YoY in Q221 according to SmartTRAK Financial Dashboard. Growth was strong across all segments and companies. However, the Delta variant may make that recovery short-lived, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 US Hemostats and Sealants Market Recap* are:

In spite of various headwinds, a strong uptick in surgical procedures and business activities in March was the slingshot effect needed to propel the US Orthobio Market into double-digit percentage growth for Q121.

In spite of the headwinds from a resurgence of COVID-19 cases in Q420 that spilled over to the early part of Q121 and winter storms of historical proportions in February, a strong uptick in elective surgical procedures in March was the slingshot effect the US Orthobio Market needed to propel it.

Among the many topics covered in detail in our comprehensive Q121 US Orthobio Market Recap* are:

The first quarter of 2021 felt like riding a car with square wheels, but ahead, the road looks smoother.

Coming out of a rough Q420 that sent the US Joint Fluid Replacement market players spinning at dizzying speed around the roulette wheel, the first quarter of 2021 gave them a bumpy ride on the road to COVID-19 recovery. As if a resurgence of positive COVID cases in late Q420 spilling into Q121 was not enough of a headwind, in mid-February, winter storms Uri and Viola landed a one-two hit across North America. 

Among the many topics covered in detail in our comprehensive Q121 US Joint Fluid Replacement Market Recap* are:

Like the ball whirling around a casino roulette wheel, COVID-19 sent the US Joint Fluid Market players bouncing and spinning off widely, with some landing the year as winners, and others not so much.

Once again COVID-19 sent players spinning at dizzying speed around the roulette wheel, all in hopes that Lady Luck would let them land unscathed for Q420. With the continued pressure from COVID impacting recovery of the healthcare system and business operations, including the US Joint Fluid Replacement, total revenue for Q420 finished lower vs Q419, according to  SmartTRAK Financial Dashboard. 

Among the many topics covered in the comprehensive Q420/FY20 US Joint Fluid Market Recap* are: